Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer
This trial is being conducted to determine the impact of whole body FDG PET-CT vs.
conventional staging in the management of patients presenting with clinical Stage III breast
cancer. Eligible consenting patients with ductal or mixed histology breast cancer will be
randomized 1:1 to whole body FDG PET-CT or conventional staging. Eligible consenting
patients with lobular only histology will be entered into a separate single arm prospective
study and will undergo whole body FDG PET-CT, CT with contrast of the chest/abdomen & pelvis
and a bone scan.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society